L-DOS 47

Drug Profile

L-DOS 47

Alternative Names: L-DOS-47

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Helix BioPharma
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Ureases
  • Mechanism of Action Urease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 18 Jul 2017 Helix BioPharma collaborates with Moffitt Cancer Center for pharmacodynamic analysis of L-DOS 47 and to investigate its therapeutic potential in combination with immune checkpoint inhibitors
  • 11 Jul 2017 Helix BioPharma collaborates with Moffitt Cancer Center for L DOS47
  • 07 Dec 2016 Efficacy, adverse event and immunogenicity data from a phase I/II trial in Non-small cell lung cancer presented at the 17th World Conference on Lung Cancer (WCLC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top